You just read:

Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists

News provided by

Protagonist Therapeutics, Inc.

May 08, 2019, 07:00 ET